Structure Therapeutics (NASDAQ:GPCR) Trading 10.9% Higher – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price shot up 10.9% during trading on Wednesday . The company traded as high as $43.00 and last traded at $44.79. 202,690 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 884,261 shares. The stock had previously closed at $40.38.

Analysts Set New Price Targets

GPCR has been the topic of several recent research reports. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a report on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Price Performance

The firm has a market cap of $2.75 billion, a PE ratio of -39.55 and a beta of -1.45. The company has a 50-day simple moving average of $49.92 and a 200-day simple moving average of $48.64.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC purchased a new stake in shares of Structure Therapeutics during the first quarter valued at $28,000. State of Wyoming bought a new position in shares of Structure Therapeutics in the second quarter worth about $28,000. IFP Advisors Inc purchased a new position in Structure Therapeutics in the 2nd quarter worth about $46,000. Assetmark Inc. increased its stake in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after buying an additional 449 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Structure Therapeutics during the 4th quarter valued at about $127,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.